UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

Multiple sclerosis, 2010-03, Vol.16 (3), p.342-350

2010

Volltextzugriff (PDF)

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients

Multiple sclerosis, 2006-06, Vol.12 (3), p.309-320

2006

Volltextzugriff (PDF)

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

Neurology, 1998-03, Vol.50 (3), p.701-708

1998

Volltextzugriff (PDF)

Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis

European journal of neurology, 2006-05, Vol.13 (5), p.471-474

2006

Volltextzugriff (PDF)

Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis

European journal of neurology, 2008-07, Vol.15 (7), p.677-680

2008

Volltextzugriff (PDF)

Predictors of well-being among significant others of persons with multiple sclerosis

Multiple sclerosis, 2007-03, Vol.13 (2), p.238-249

2007

Volltextzugriff (PDF)

Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis: Results of a phase III multicenter, double‐blind, placebo‐controlled trial

Neurology, 1995-07, Vol.45 (7), p.1268-1276

1995

Volltextzugriff (PDF)

Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for immune-related molecules by central nervous system mixed glial cell cultures

Multiple sclerosis, 2006-04, Vol.12 (2), p.149-168

2006

Volltextzugriff (PDF)

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

Multiple sclerosis, 2000-08, Vol.6 (4), p.255-266

2000

Volltextzugriff (PDF)

Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data

Acta neurologica Scandinavica, 2005-01, Vol.111 (1), p.42-47

2005

Volltextzugriff (PDF)

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

Multiple sclerosis, 2000-04, Vol.6 (4), p.255-266

2000

Volltextzugriff (PDF)

Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial

Multiple sclerosis, 2003-12, Vol.9 (6), p.585-591

2003

Volltextzugriff (PDF)

Acute transverse myelitis with normal brain MRI: Long-term risk of MS

Journal of neurology, 2008, Vol.255 (1), p.89-93

2008

Volltextzugriff (PDF)

The Role of Cytokines in Schwann Cell Damage, Protection, and Repair

The Journal of infectious diseases, 1997-12, Vol.176 (Supplement-2), p.S173-S179

1997

Volltextzugriff (PDF)

Intercaudate nucleus ratio as a linear measure of brain atrophy in multiple sclerosis

Neurology, 2003-01, Vol.60 (2), p.323-325

2003

Volltextzugriff (PDF)

Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis

Multiple sclerosis, 2013-02, Vol.19 (2), p.130-136

2013

Volltextzugriff (PDF)

Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells

Multiple sclerosis, 2001-02, Vol.7 (1), p.43-47

2001

Volltextzugriff (PDF)

Expression of Urokinase Plasminogen Activator Receptor on Monocytes from Patients with Relapsing-Remitting Multiple Sclerosis: Effect of Glatiramer Acetate (Copolymer 1)

Clinical and Diagnostic Laboratory Immunology, 2001-11, Vol.8 (6), p.1196-1203

2001

Volltextzugriff (PDF)

Failure to develop multiple sclerosis in patients with neurologic symptoms without objective evidence

Multiple sclerosis, 2008-07, Vol.14 (6), p.804-808

2008

Volltextzugriff (PDF)

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

The New England journal of medicine, 2008-10, Vol.359 (17), p.1786-1801

2008

Volltextzugriff (PDF)

Epstein-Barr virus encephalomyelitis diagnosed by polymerase chain reaction: detection of the genome in the CSF

Neurology, 1997-05, Vol.48 (5), p.1351-1355

1997

Volltextzugriff (PDF)

Circulating, soluble adhesion proteins in cerebrospinal fluid and serum of patients with multiple sclerosis: Correlation with clinical activity

Annals of neurology, 1995-01, Vol.37 (1), p.55-62

1995

Volltextzugriff (PDF)

Myasthenia gravis patients, but not healthy subjects, recognize epitopes that are unique to the epsilon-subunit of the acetylcholine receptor

Journal of neuroimmunology, 2005-02, Vol.159 (1-2), p.137-145

2005

Volltextzugriff (PDF)

Guillain-Barré syndrome (GBS) with bilateral optic neuritis and central white matter disease

Neurology, 1993-04, Vol.43 (4), p.842-842

1993

Volltextzugriff (PDF)

Polymerase chain reaction analysis of human herpesvirus-6 sequences in the sera and cerebrospinal fluid of patients with multiple sclerosis

Journal of neurovirology, 1999-04, Vol.5 (2), p.134-139

1999

Volltextzugriff (PDF)

1 – 25 von 488

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(424)
Mit Volltextzugriff
(368)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis

Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis

Predictors of well-being among significant others of persons with multiple sclerosis

Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis: Results of a phase III multicenter, double‐blind, placebo‐controlled trial

Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for immune-related molecules by central nervous system mixed glial cell cultures

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial

Acute transverse myelitis with normal brain MRI: Long-term risk of MS

The Role of Cytokines in Schwann Cell Damage, Protection, and Repair

Intercaudate nucleus ratio as a linear measure of brain atrophy in multiple sclerosis

Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis

Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells

Expression of Urokinase Plasminogen Activator Receptor on Monocytes from Patients with Relapsing-Remitting Multiple Sclerosis: Effect of Glatiramer Acetate (Copolymer 1)

Failure to develop multiple sclerosis in patients with neurologic symptoms without objective evidence

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

Epstein-Barr virus encephalomyelitis diagnosed by polymerase chain reaction: detection of the genome in the CSF

Circulating, soluble adhesion proteins in cerebrospinal fluid and serum of patients with multiple sclerosis: Correlation with clinical activity

Myasthenia gravis patients, but not healthy subjects, recognize epitopes that are unique to the epsilon-subunit of the acetylcholine receptor

Guillain-Barré syndrome (GBS) with bilateral optic neuritis and central white matter disease

Polymerase chain reaction analysis of human herpesvirus-6 sequences in the sera and cerebrospinal fluid of patients with multiple sclerosis

Suchergebnisse filtern